An Observational Study to Assess Change in Disease Activity and Treatment Patterns of Upadacitinib When Given Alone or Co-Administered With Methotrexate in Adult Participants With Active Psoriatic Arthritis

Study Identifier
P22-897
CT.gov Identifier
NCT05616871
EudraCT Identifier
Not available
EUCTIS ID
Not available
For general inquiries, please contact

844-663-3742 or [email protected]

Recruitment Complete
Sign up for trial alerts

Study Details

Medical Condition
  • Psoriatic Arthritis (PsA)
    • Study Drug
    N/A
    Phase
    N/A
    Sex
    Female & Male
    Age
    18+ years
    Inclusion and Exclusion Criteria
    Inclusion Criteria:
    * Confirmed diagnosis of active psoriatic arthritis (PsA) whose peripheral involvement justifies the prescription of upadacitinib upon judgement of the treating physician. * Physician decision on participant treatment with upadacitinib must have been reached prior to and independently of recruitment in the study. * Upadacitinib prescribed in accordance with the applicable approved label and local regulatory and reimbursement policies. * Participants able to understand and communicate with the investigator and comply with the requirements of the study.
    Exclusion Criteria:
    * Participation in a clinical trial of an investigational drug, concurrently or within the last 30 days. * Prior treatment with upadacitinib.

    Protocol Summary

    Psoriatic arthritis (PsA) is a chronic, immune-mediated, systemic disease affecting less than 1% of people with variations by parts of the world, and around 20%-30% of participants with psoriasis.

    Upadacitinib (RINVOQ) is approved drug for the treatment of adult participants with active PsA in Europe. Approximately 450 adult participants who are prescribed Upadacitinib by their physician in accordance with local label will be enrolled in 4 countries in Europe: France, Germany, Greece and Italy.

    Participants will receive upadacitinib as prescribed by their physician according to their routine clinical practice and local label. Participants will be followed for up to 24 months.

    There is expected to be no additional burden for participants in this trial. Participants will attend regular visits during the study at a hospital or clinic according to their routine clinical practice.

    Study Locations

    Location
    Status
    Location
    Centre Hospitalier Universitaire de Nice - Hôpital Pasteur /ID# 252536
    Nice, Alpes-Maritimes, France, 06001
    Status
    Not applicable
    Location
    CH Troyes - Hopital Simone Veil /ID# 252625
    Troyes, Aube, France, 10000
    Status
    Not applicable
    Location
    CHU de Besancon - Jean Minjoz /ID# 252537
    Besançon, Doubs, France, 25030
    Status
    Not applicable
    Location
    CHU Limoges - Dupuytren 1 /ID# 252432
    Limoges, Franche-Comte, France, 87042
    Status
    Not applicable
    Location
    CHU Toulouse - Hopital Purpan /ID# 252077
    Toulouse, Haute-Garonne, France, 31059
    Status
    Not applicable
    Location
    CHU Montpellier - Hopital Saint Eloi /ID# 252078
    Montpellier, Herault, France, 34295
    Status
    Not applicable
    Showing {first} - {last} of {total} Results